Vol.64

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.63

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.62

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.61

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.60

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.59

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.58

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.57

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.56

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.55

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.54

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.53

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12

Vol.52

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12

Vol.51

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12

Vol.50

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12

Vol.49

• No.1
• No.2/3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12

Vol.48

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12

• Vol.47 to 1
  (Members Only)

• HOME
• Vol.60 No.3
• CLINICA NEUROL, 60: 223−228, 2020
• Vol.60 No.3 contents

Case Report

Thrombolytic recombinant tissue plasminogen activator (rt-PA) treatment in the acute ischemic stroke with limb arterial embolism; three case reports

Atsunori Murao, M.D.¹⁾, Toshihiro Endo, M.D.¹⁾²⁾, Tomoya Nisii, M.D.²⁾³⁾, Yousuke Tamari, M.D.²⁾³⁾, Hiroaki Tamai, M.D.⁴⁾ and Shinichi Terao, M.D.¹⁾²⁾⁵⁾

¹⁾Department of Neurology, Kasugai City Hospital
²⁾Department of Stroke Center, Kasugai City Hospital
³⁾Department of Neurosurgery, Kasugai City Hospital
⁴⁾Department of Vascular Surgery, Kasugai City Hospital
⁵⁾Present address: Department of Internal Medicine, Mitaki General Hospital

We report three female patients, aged 77, 89, and 92 years, with arterial emboli in their limbs that developed before and after recombinant tissue plasminogen activator (rt-PA) treatment for cerebral infarction. Arterial embolism in one limb developed in two patients before rt-PA treatment and in one during rt-PA treatment at the time of the first medical examination. Thrombectomy was performed in two patients. In all patients, the arterial emboli of the extremities were accompanied by acute cardiogenic cerebral emboli. Patients with cardiogenic cerebral emboli can also develop emboli in the extremities. Particularly, during rt-PA treatment of cerebral infarction, the presence of other possible thromboembolisms, in addition to hemorrhagic complications and changes in neurological symptoms, should be examined.
Full Text of this Article in Japanese PDF (2052K)

(CLINICA NEUROL, 60: 223−228, 2020)
key words: cerebral infarction, rt-pa, thrombolysis, cardiogenic embolism, arterial embolism

(Received: 25-Oct-19)